Long-Term Safety and Efficacy of the Selective Aldosterone Blocker Eplerenone in Patients with Essential Hypertension

Clinical Therapeutics

Volumn 25, Issue 9, 2003, Pages 2388-2404

  Burgess, Ellen D ^a,f   Lacourcière, Yves ^b   Ruilope Urioste, Luis M ^c   Oparil, Suzanne ^d   Kleiman, Jay H ^e   Krause, Scott ^e   Roniker, Barbara ^e   Maurath, Clement ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

^f FOOTHILLS HOSPITAL   (Canada)

Author keywords

Aldosterone; Eplerenone; Hypertension; Selective aldosterone blocker

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE;

ACCIDENT; ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOTENSION; INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NAUSEA; PERIPHERAL EDEMA; SIDE EFFECT; SINUSITIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

EID: 0142043927     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80282-5     Document Type: Article

References (33)

1. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000.
2. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
3. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
4. Funder J. Mineralocorticoids and cardiac fibrosis: The decade in review. Clin Exp Pharmacol Physiol. 2001;28:1002-1006.
5. Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis. 2001;37:677-688.
6. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045.
7. Nishimura M, Uzu T, Fujii T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999;33:261-266.
8. El-Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845-850.
9. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
10. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
11. Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269:24316-24320.
12. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: A selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev. 2001;19:185-200.
13. Lombès M, Farman N, Bonvalet JP, Zennaro MC. Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris). 2000;61:41-46.
14. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
15. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
16. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999;33:232-237.
17. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
18. Kurtz TW, Catanzaro DF. New frontiers in aldosterone/mineralocorticoid biology: A reemerging force in target organ damage and hypertension. Am J Hypertens. 2001;14: 1276-1277.
19. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spironolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656.
20. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
21. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-1155.
22. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117-123.
23. Pitt B, Reichek N, Metscher B, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. J Am Coll Cardiol. 2002;39(Suppl A):249A. Abstract.
24. Epstein M, Buckalew V, Altamirano J, et al. Eplerenone reduces proteinuria in type II diabetes mellitus: Implications for aldosterone involvement in the pathogenesis of renal dysfunction. J Am Coll Cardiol. 2002;39(Suppl A):250A. Abstract.
25. Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Disease of the Heart and Great Vessels. 9th ed. Boston: Little, Brown and Company; 1994.
26. Tarif N, Bakris GL. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int Suppl. 1997;63:S67-S70.
27. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97-107.
28. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:26-32.
29. Ruilope LM, Aldigier JC, Ponticelli C, et al, for the European Group for the Investigation of Valsartan in Chronic Renal Disease. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens. 2000;18:89-95.
30. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460-463.
31. Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy. 2001;21:676-683.
32. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351-357.
33. Spilker B. Standardized information across protocols (polishing the boilerplate). In: Guide to Clinical Studies and Developing Protocols. New York: Raven Press; 1984:154-184.